| Introduction to CAR T-Cell Therapy |
|
In this Educator Module, Justin Speyer, MSN, ARNP, FNP-BC, of Fred Hutchinson Cancer Research Center and University of Washington Medical Center, provides a comprehensive overview of CAR T-cell therapy, including currently approved and emerging options and how they compare with chemotherapy and other immunotherapy modalities. Mr. Speyer also discusses the CAR T-cell treatment process for patients and common treatment-related toxicities associated with these therapies. Funding and support provided by Bristol Myers Squibb and Kite, a Gilead Company
Take a short survey and earn your certificate of participation!
APSHO members: Login here APSHO non-members: Create an APSHO guest non-member profile first by clicking here. Once you’ve created your APSHO profile, follow the prompts to the survey and the certificate. Meet The Faculty
Lead Author
Justin Speyer, MSN, ARNP, FNP-BC
Fred Hutchinson Cancer Center Justin Speyer is a family care nurse practitioner who has found a home in inpatient oncology for the past 14 years. He has had the opportunity to manage all manner of malignancies from diagnosis through end of life. He has a particular interest
and passion for the management of hematopoietic malignancies, especially AML, APL, and ALL. He is ecstatic to have had a front-row seat for the demise of high-dose IL-2 therapy and the birth of modern immunotherapy and remains excited
for the future of oncology each and every day. When he is not in the hospital performing lumbar punctures and bone marrows and managing chemotherapy, he can often be found road biking around the Puget Sound region or parenting his precocious
10-year-old daughter.
Reviewer
Michelle Lauer, PA-C, MPH
Stanford Healthcare Michelle Lauer is a physician assistant at Stanford Healthcare in Palo Alto, California. She completed her PA studies at Arcadia University in Glenside, Pennsylvania, in 2016. Since then, she has worked at multiple academic medical centers
to help care for patients with hematologic malignancies undergoing chemotherapy, transplant, and immunotherapy treatment. She currently works in the Bone Marrow Transplantation and Cell Therapy Division at Stanford.
Reviewer
Meaghan Ryan, MSN, FNP-BC
Barnes-Jewish Hospital & Washington University School of Medicine Meaghan Ryan is a lead inpatient nurse practitioner at Barnes-Jewish Hospital and Washington University School of Medicine. Her clinical practice primarily focuses on inpatient management of patients with hematologic malignancies, including
stem cell transplant and cellular therapies. She also serves in a lead role of the inpatient APP team.
|